Trial Profile
Pivotal study of lorvotuzumab mertansine + carboplatin + etoposide in patients with Merkel cell carcinoma
Status:
Not stated
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 02 Feb 2011
Price :
$35
*
At a glance
- Drugs Lorvotuzumab mertansine (Primary) ; Carboplatin; Etoposide
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Sponsors ImmunoGen
- 02 Feb 2011 New trial record